Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
Researchers want to see how well EP0031 works to treat cancer. The people in this study have solid tumors with a mutation (change) in a gene called RET.
The purpose of this study is to assess the safety and effectiveness of combination therapy with zanubrutinib, obinutuzumab, and venetoclax in patients newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
The purpose of this study is to find the highest dose of the investigational immunotherapy 2141-V11 that can be given safely in people with bladder cancer that has not invaded the bladder muscle wall, has come back after BCG therapy, and will not be surgically removed. The drug 2141-V11 attaches to a protein on immune cells and activates the immune system to find and kill bladder cancer cells. It is given directly into the bladder through a catheter (flexible tube).
Ibrutinib and rituximab are the standard treatment for Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LL). In this study, researchers want to see if giving the medication venetoclax with the standard treatment is safe and more effective than the standard treatment alone in people with previously untreated WM/LL.
The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.
Cancer and its treatment can cause problems with attention, memory, and learning. These cognitive difficulties may affect your daily activities and worsen your quality of life.
